A mitochondrial-targeting adaptive artificial ion channel, its preparation method and application
By designing the mitochondrial-targeting adaptive artificial ion channel compound Pn-TPP, the problem of existing artificial ion channels being unable to specifically target cancer cells has been solved, achieving selective killing of cancer cells and reducing toxic side effects on normal cells, showing significant anti-cancer potential.
Patent Information
- Application Number
- CN202410129577.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-31
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-01-31
AI Technical Summary
Existing artificial ion channels are difficult to specifically target cancer cells, resulting in chemotherapy drugs having high toxicity to normal cells as well, and drug resistance seriously affects the efficacy of chemotherapy.
A mitochondrial-targeting adaptive artificial ion channel compound, Pn-TPP, was designed. By linking cholic acid groups with triphenylphosphine groups, a concentration-dependent adaptive artificial ion channel is formed. It can self-assemble into a chloride ion channel at low concentrations and form a nanopore for transmembrane transport of small molecules at high concentrations, specifically acting on the mitochondrial membrane of cancer cells.
The compound Pn-TPP exhibits a unique ability to self-assemble into chloride ion channels at low concentrations and form nanopores at high concentrations. It can selectively target the mitochondria of cancer cells, triggering the apoptosis pathway and showing significant anticancer activity and selectivity. Its IC50 value is comparable to that of commonly used chemotherapy drugs in clinical practice, and its selectivity index is an order of magnitude higher than that of doxorubicin.
Smart Images

Figure CN118184725B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to an adaptive artificial ion channel with mitochondrial targeting, its preparation method, and its application. Background Technology
[0002] Cancer is one of the world's leading health problems and the second leading cause of death globally. Currently, chemotherapy remains the primary treatment for cancer; however, commonly used chemotherapy drugs such as doxorubicin, paclitaxel, and cisplatin generally lack cell specificity and have high toxicity to normal cells. Drug resistance also severely impacts the effectiveness of chemotherapy. Therefore, there is an urgent need to develop anticancer drugs based on novel anticancer mechanisms that can specifically target tumor tissue.
[0003] Artificial ion channels with high transmembrane transport activity hold promise for developing into a new class of anticancer drugs based on novel mechanisms of action, as they can rapidly disrupt the ion balance across cell membranes or organelle membranes, thereby inducing apoptosis. Unfortunately, existing artificial ion channels still struggle to achieve specificity against cancer cells, and developing new artificial ion channels that can selectively target cancer cells while minimizing impact on normal cells remains a significant challenge.
[0004] Mitochondria are the energy factories of cellular life activities. During oxidative phosphorylation, the mitochondrial transmembrane potential (ΔΨm), generated by the proton pump, is a crucial component of energy storage. The mitochondrial membrane potential of normal cells is 130–150 mV. Compared to normal cells, cancer cells, due to their abnormally vigorous metabolism, have a higher mitochondrial membrane potential (180–200 mV). If the transmembrane potential is disrupted, leading to mitochondrial depolarization, the mitochondria release cytochrome C into the cytoplasm, subsequently initiating mitochondrial-mediated apoptosis. Therefore, the development of MMP-driven artificial ion channels targeting mitochondria may provide a promising approach for selectively killing cancer cells. Unfortunately, no artificial ion channels that can directly target mitochondria have yet been reported. Summary of the Invention
[0005] In view of this, the purpose of this invention is to provide a mitochondrial-targeted adaptive artificial ion channel, its preparation method, and its application. This invention constructs the first concentration-dependent adaptive artificial ion channel by linking cholic acid groups and triphenylphosphine (TPP) groups through three to seven ethylene glycol units.
[0006] The specific technical solution adopted in this invention is as follows:
[0007] The first objective of this invention is to provide a mitochondrial-targeted adaptive artificial ion channel, wherein the compound Pn-TPP with the mitochondrial-targeted adaptive artificial ion channel has the following general structural formula:
[0008]
[0009] Where n takes values from 3 to 7.
[0010] The second objective of this invention is to provide a synthetic route for the above-mentioned compound Pn-TPP, as follows:
[0011]
[0012] The specific synthetic process is as follows: Cholic acid is linked with polyethylene glycol monotoluenesulfonate esters of different chain lengths via a nucleophilic substitution reaction to prepare an intermediate compound. Subsequently, the intermediate compound is reacted with 2-(carboxyethyl)triphenylphosphine chloride in the presence of the condensing agent BOP to form the final product compound Pn-TPP. The synthetic route of this invention is green, environmentally friendly, simple, efficient, and uses readily available raw materials, and can be used for the synthesis of similar compounds.
[0013] Preferably, the compound Pn-TPP self-assembles into chloride ion channels at low concentrations and into nanopores capable of transporting small molecules across membranes at high concentrations.
[0014] Furthermore, the low concentration is ≤1.25μM, and the high concentration is ≥4μM.
[0015] A third objective of this invention is to provide the application of the aforementioned mitochondrial-targeted adaptive artificial ion channel, specifically the use of the compound Pn-TPP in the preparation of antitumor drugs.
[0016] Furthermore, the antitumor drug is an anti-liver cancer drug.
[0017] A fourth object of the present invention is to provide the application of the above-mentioned adaptive artificial ion channel with mitochondrial targeting, and the use of the compound Pn-TPP as an anticancer therapeutic compound in anticancer therapy.
[0018] Furthermore, the compound Pn-TPP induces apoptosis in human liver cancer cells (HepG2 cells);
[0019] Furthermore, the compound Pn-TPP is specifically localized in the mitochondria of cancer cells;
[0020] Furthermore, the compound Pn-TPP causes mitochondrial membrane depolarization and leads to an increase in ROS content in cancer cells, which in turn triggers the release of cytochrome c from mitochondria into the cytoplasm.
[0021] Furthermore, the compound Pn-TPP downregulates typical anti-apoptotic proteins MCL1 and BCL2 and affects the expression levels of Cleaved Caspase 9, PARP, and Cleaved PARP proteins, triggering the Caspase 9 apoptosis pathway.
[0022] A fifth object of the present invention is to provide a pharmaceutical composition comprising the above-described adaptive artificial ion channel having mitochondrial targeting and a pharmaceutically or reasonably acceptable carrier and / or excipient.
[0023] The sixth object of this invention is to provide a compound Pn-TPP-py, which is obtained by modifying compound Pn-TPP with a fluorescent group. Furthermore, the synthetic route of compound Pn-TPP-py is as follows:
[0024]
[0025] The beneficial effects of this invention are as follows: Based on the significant difference in mitochondrial transmembrane potential between cancer cells and normal cells, this invention designs a novel class of adaptive artificial ion channels using triphenylphosphine cationic TPP as a targeting group for cancer cell mitochondria. These molecules can specifically act on cancer cells, reducing toxic side effects on normal cells. At low concentrations, the molecules exhibit a unique ability to self-assemble into chloride ion channels, while at higher concentrations they transform into nanopores capable of transmembrane transport of small molecules. The TPP group endows these molecules with mitochondrial targeting properties, enabling them to selectively form channels on the mitochondrial membrane of cancer cells, thereby triggering the caspase 9 apoptosis pathway. The anticancer activity of Pn-TPPs is related to their ability to form nanopores, among which P5-TPP shows significant anticancer potential against human liver cancer cells, with an IC50 value of [missing information]. 50 The concentration was 3.8 μM, comparable to that of doxorubicin, a commonly used chemotherapy drug. More importantly, P5-TPP maintained significant selectivity for liver cancer cells, with a selectivity index of 4.4, more than an order of magnitude higher than that of doxorubicin. This indicates that artificial ion channels have great potential in anti-cancer applications and could be developed into a class of specific anti-cancer drugs.
[0026] Experiments have shown that:
[0027] The compounds involved in this invention are concentration-driven adaptive artificial ion channels, meaning they self-assemble into chloride ion channels at low concentrations and transform into nanopores capable of transporting small molecules across membranes at high concentrations. A detailed description follows:
[0028] pH-sensitive HPTS vesicle fluorescence experiments demonstrated that the compound possesses transmembrane transport activity, and the transport mechanism was determined to be Cl. - / H + Cotransport or Cl- / OH - Reverse transfer.
[0029] Based on FCCP and VA experiments, the ion transport rate of the compound was demonstrated to be Cl. - >H + and Cl - >OH - .
[0030] Based on chloride ion-sensitive SPQ vesicle fluorescence experiments, the compound exhibits excellent chloride ion transmembrane transport activity at low concentrations.
[0031] Based on CF dye penetration experiments, the compound formed macropores with nanoscale cavities at high concentrations.
[0032] Experiments based on single-molecule channel currents have demonstrated that compounds adaptively assemble into artificial channels with different pore sizes based on their varying concentrations in the membrane.
[0033] In vitro antitumor experiments showed that the compound exhibited good anticancer activity and selectivity, demonstrating potential value in the development of antitumor drugs. Details are as follows:
[0034] The compound obtained in this invention can induce apoptosis in human liver cancer cells (HepG2 cells) and exhibits selectivity for liver cancer cells compared to normal liver cells (HHL-5), with a selectivity index (SI) of 4.4.
[0035] The compounds obtained in this invention can be specifically localized in the mitochondria of cancer cells.
[0036] The compound obtained by this invention can cause depolarization of mitochondrial membrane potential and lead to an increase in ROS content in cancer cells, which in turn triggers the release of cytochrome c from mitochondria into the cytoplasm.
[0037] The compounds obtained in this invention can downregulate typical anti-apoptotic proteins MCL1 and BCL2 and affect the expression levels of proteins such as Cleaved Caspase 9, PARP, and Cleaved PARP, thereby triggering the Caspase 9 apoptosis pathway. Attached Figure Description
[0038] Figure 1 Schematic diagram of the transmembrane transport activity of different Pn-TPP channel molecules;
[0039] Figure 2 This is a schematic diagram of the transmembrane transport activity of P7-TPP channel molecules at different concentrations.
[0040] Figure 3 A schematic diagram illustrating the selectivity of P7-TPP ion transmembrane transport;
[0041] Figure 4 A schematic diagram of the ion transmembrane transport rate (FCCP) of P7-TPP;
[0042] Figure 5 A schematic diagram of the ion transmembrane transport rate (VA) of P7-TPP;
[0043] Figure 6 A schematic diagram of chloride ion transmembrane transport activity at different concentrations of P7-TPP channel molecules;
[0044] Figure 7 Schematic diagram of chloride ion transmembrane transport activity of different Pn-TPP channel molecules;
[0045] Figure 8 A schematic diagram illustrating the pore size of the channels formed by P7-TPP at different concentrations for qualitative evaluation of CF dye leakage experiments.
[0046] Figure 9 Schematic diagrams of single-channel current traces (a and c) and current-voltage (IV) curves (b and d) of P5-TPP in a symmetrical bath;
[0047] Figure 10 This is a schematic diagram illustrating the colocalization of Mito-Tracker Red and P5-TPP-py fluorescence signals.
[0048] Figure 11 This is a schematic diagram illustrating P5-TPP-induced apoptosis in HepG2 cells.
[0049] Figure 12 A schematic diagram illustrating the depolarization of mitochondrial membrane potential caused by P5-TPP.
[0050] Figure 13 A schematic diagram illustrating the changes in intracellular ROS levels caused by P5-TPP.
[0051] Figure 14 A schematic diagram illustrating the release of cytochrome c induced by P5-TPP;
[0052] Figure 15 This is a schematic diagram of the immunoblotting analysis of HepG2 cells by P5-TPP. Detailed Implementation
[0053] The artificial potassium ion transporter with anti-liver fibrosis activity provided by the present invention, its preparation method, and its application are described in further detail and completely below with reference to embodiments. The embodiments described below are exemplary and are only used to explain the present invention, and should not be construed as limiting the present invention.
[0054] "Pharmaceutically acceptable carriers or excipients" refers to one or more compatible solid or liquid fillers or gelling substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can interact with and blend with the active ingredient of the invention without significantly reducing the efficacy of the active ingredient. Examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g.), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0055] This invention provides a compound Pn-TPP with a mitochondrial-targeted adaptive artificial ion channel, the general structural formula of which is as follows:
[0056]
[0057] Where n takes values from 3 to 7.
[0058] The synthetic route for compound Pn-TPP is also provided, as follows:
[0059]
[0060] This invention also provides a compound Pn-TPP-py, which is obtained by modifying compound Pn-TPP with a fluorescent group. Further, the synthetic route of compound Pn-TPP-py is as follows:
[0061]
[0062] The present invention will be further described in detail below with reference to specific embodiments.
[0063] Example 1
[0064] P3-TPP
[0065] Add DIEA (0.35 mL, 2.0 mmol). Stir the reaction mixture at room temperature for 24 hours. After evaporating the organic solvent under vacuum, dissolve the reaction mixture in dichloromethane (30 mL), wash three times with water (30 mL), and then purify by column chromatography (methanol:dichloromethane = 7:100) to give pure P3-TPP as a colorless liquid. Yield: 0.21 g, 23%. 1H NMR(600MHz,CDCl3)δ7.83(m,3H),7.71(m,12H),4.18(m,2H),4.11(m,2H),3.95(s,1H),3.84(s,1H),3.63(m,10H),3.43(m,1H),2.81(dd,J=14.4,7.2Hz,2H),2.36(s,1H),2.21(m,3H),1.79(m,16H),1.38(m,3H),1.11(m,1H),0.97(d,J=6.1Hz,3H),0.88(s,3H),0.67(s,3H). 13 CNMR(151MHz,CDCl3)δ174.4,170.2,135.5,133.5,130.8,117.6,117.0,73.0,71.9,70.5,70.3,69.0,68.6,68.4,65.0,63.4,46.8,46.4,41.8,41.4,39.6,35.2,34.7,34.6,31.0,30.8,30.4,29.5,28.2,27.5,27.2,26.926.5,23.2,22.7,22.5,18.1,17.7,17.3,12.5.MS-ESI:calculated for[M-Cl] + (C 51 H 70 O9P):m / z 857.4752,found:m / z 857.4761.
[0066] P4-TPP
[0067]
[0068] 3.88(s,1H),3.76(s,1H),3.57(d,J=26.1Hz,14H),3.34(s,1H),2.75(d,J=7.1Hz,2H),2.29(d,J=10.5Hz,1H),2.15(m,3H),1.65(m,16H),1.31(s,3H),1.01(s,1H),0.89(d,J=5.0Hz,3H),0.81(s,3H),0.59(s,3H). 13C NMR(151MHz,CDCl3)δ174.5,170.2,135.6,133.5,130.8,117.6,117.0,73.1,71.9,70.5,69.1,68.6,68.5,65.0,63.5,46.9,46.4,41.7,41.5,39.5,35.3,34.7,31.1,30.9,30.3,29.7,29.4,28.1,27.5,26.9,26.4,23.3,22.2,18.1,17.8,17.3,12.5.MS-ESI:calculated for[M-Cl] + (C 53 H 74 O 10 P):m / z901.5014,found:m / z 901.5026.
[0069] P5-TPP
[0070]
[0071] 2.5Hz,2H),4.09(s,2H),3.97(s,1H),3.84(s,1H),3.74(m,1H),3.62(m,17H),3.46(s,1H),2.82(m,2H),2.36(d,J=10.8Hz,1H),2.23(m,3H),1.67(ddt,J=38.4,23.9,12.2Hz,14H),1.37(s,4H),1.27(d,J=18.3Hz,1H),1.08(s,1H),0.96(d,J=5.5Hz,3H),0.87(s,3H),0.66(s,3H). 13 C NMR(151MHz,CDCl3)δ174.5,170.2,135.6,133.5,130.8,117.6,117.0,73.2,72.1,70.5,69.1,68.6,64.9,63.5,46.9,46.4,41.7,41.4,39.4,39.0,35.3,34.8,34.5,31.1,30.8,29.9,28.1,27.5,26.9,26.4,23.2,22.5,18.1,17.7,17.3,12.5.MS-ESI:calculated for[M-Cl] + (C 55 H 78 O 11 P):m / z 945.5276,found:m / z 945.5275.
[0072] P6-TPP
[0073]
[0074] 4.18(m,2H),3.96(s,1H),3.84(d,J=2.3Hz,1H),3.69(s,2H),3.64(m,18H),3.58(m,2H),3.43(d,J=4.4Hz,1H),2.82(m,2H),2.38(s,1H),2.22(dd,J=25.6,13.4Hz,3H),1.77(m,15H),1.38(dd,J=11.6,4.2Hz,3H),1.29(s,1H),1.11(m,1H),0.97(d,J=6.2Hz,3H),0.88(s,3H),0.67(s,3H). 13 C NMR(151MHz,CDCl3)δ174.7,170.6,135.5,133.5,130.8,117.6,117.0,73.0,71.9,70.3,70.1,69.3,69.0,68.4,64.8,63.3,46.9,46.5,41.9,41.5,39.6,35.2,34.7,31.1,30.8,30.4,29.8,29.4,28.3,27.5,26.9,26.6,23.2,22.5,18.2,17.8,17.4,12.6.MS-ESI:calculated for[M-Cl] + (C 57 H 82 O 12 P):m / z 989.5538,found:m / z989.5542.
[0075] P7-TPP
[0076]
[0077] 1H),3.85(s,1H),3.69(d,J=2.7Hz,2H),3.64(m,24H),3.43(s,1H),2.83(m,2H),2.38(m,1H),2.22(m,3H),1.89(d,J=7.0Hz,3H),1.68(m,12H),1.39(d,J=12.0Hz,4H),1.12(m,1H),0.98(d,J=4.7Hz,3H),0.89(s,3H),0.68(s,3H). 13C NMR (151MHz, CDCl3) δ174.4,170.2,135.6,133.5,130.8,117.6,117.0,73. 0,71.9,70.4,69.2,68.7,68.4,64.9,63.5,47.0,46.5,41.9,41.5,39.7,3 9.6,36.0,35.3,34.7,31.1,30.8,30.5,29.8,29.4,28.3,27.5,27.3,26.9 ,26.6,25.6,23.2,22.8,22.7,18.1,17.8,17.4,12.6.MS-ESI:calculated for[M-Cl] + (C 59 H 86 O 13 P): m / z 1033.5801, found: m / z 1033.5812.
[0078] Example 2
[0079] Synthesis of P5-TPP-py
[0080] P5-TPP (110.2 mg, 0.12 mmol), 3b (42.0 mg, 0.15 mmol), and BOP (79.5 mg, 0.18 mmol) were dissolved in DMF (15 mL), and DIEA (42 μL, 0.24 mmol) was added. The reaction mixture was stirred at 25 °C for 24 hours. After the organic solvent evaporated, the crude product was dissolved in dichloromethane.
[0081]
[0082] Colored liquid. Yield: 19.3 mg, 13%. 1¹H NMR (600 MHz, CDCl₃) δ 8.53 (d, J=9.1 Hz, 1H), 8.09 (m, 4H), 7.96 (m, 2H), 7.90 (d, J=8.9 Hz, 1H), 7.79 (t, J=7.2 Hz, 3H), 7.67 (ddd, J=17.6, 10.6, 4.3 Hz, 11H), 7.43 (d, J=8.4 Hz, 1H), 4.93 (s, 2H), 4.76 (m, 1H), 4.20 (m, 2H), 4.09 (m, 2H), 3.92 (s, 1H), 3.81 (d, J=2.2 Hz, 1H), 3.68 (t, J=4.8 Hz, 2H), 3.62 (dd, J=14.5, 7.3 Hz, 13H), 3.57 (dd, J=12.7, 7.3 Hz, 3H), 2.79 (dt, J=14.7, 7.4 Hz, 2H), 2.28 (m, 4H), 2.14 (dd, J=12.0, 7.8 Hz, 1H), 1.92 (m, 9H), 1.78 (s, 1H), 1.71 (t, J=9.6 Hz, 2H), 1.62 (m, 1H), 1.51 (m, 5H), 1.11 (dd, J=12.1, 6.0 Hz, 1H), 0.96 (d, J=6.2 Hz, 3H), 0.86 (s, 3H), 0.64 (s, 3H). 13 ¹³C NMR (151 MHz, CDCl₃) δ 174.3, 170.2, 168.7, 152.0, 135.5, 133.5, 132.1, 131.6, 130.8, 130.0, 128.6, 127.2, 126.8, 126.2, 126.1, 125.9, 125.5, 125.4, 124.8, 124.5, 121.4, 120.9, 117.6, 117.0, 109.7, 75.8, 72.9, 70.5, 69.2, 68.6, 68.2, 66.9, 64.9, 63.5, 47.1, 46.5, 42.0, 41.2, 39.5, 35.1, 34.7, 34.3, 32.0, 31.6, 31.1, 30.8, 29.8, 29.4, 28.3, 27.5, 27.3, 26.9, 26.7, 23.1, 22.7, 22.5, 18.1, 17.8, 17.4, 14.2, 12.6. MS-ESI: calculated for [M-Cl] + (C 59 H 86 O 13 P): m / z 1205.6114, found: m / z 1205.5992.
[0083] Example 3
[0084] Detection of transmembrane transport activity of compounds
[0085] Ion transport studies based on HPTS vesicle fluorescence experiments:
[0086] 1.0 mL of egg-yolk phosphatidylcholine (EYPC, 25 mg / mL) chloroform solution was placed in a round-bottom flask. The solvent was removed under reduced pressure at room temperature, and the flask was dried overnight under high vacuum. Hydration was carried out at room temperature by shaking 1.0 mL of pH-sensitive HTPS (0.1 mM, pH = 7.0, 100 mM NaCl, 10 mM HEPES). After 1 hour, the round-bottom flask was frozen in liquid nitrogen for 1 minute, then heated in a water bath at room temperature for 2 minutes. This freeze-thaw cycle was repeated 10 times. The suspension was then passed through a 100 nm pore size polycarbonate membrane and extruded 21 times to obtain a uniformly sized vesicle (LUV) suspension. Finally, the uncoated fluorescent dye in the LUV suspension was dialyzed off using a dialysis membrane to produce a 6.5 mM lipid LUV.
[0087] 30 μL of LUV suspension coated with HPTS was added to 1.95 mL of NaCl buffer solution (pH = 8.0, 100 mM NaCl, 10 mM HEPES). After adding channels of different concentrations with stirring, the fluorescence intensity change at the emission wavelength of 510 nm was detected using a fluorescence spectrophotometer (Hitachi, model F-7100, Japan) under dual-wavelength excitation at 403 nm and 460 nm for 300 seconds. The final transmission curve was obtained by calculating I... 460 / I 403 The ratio value, and after adding triton, I is obtained through equation (1). 460 / I 403 The ratio values are normalized.
[0088] I f =[(I t -I0) / (I1-I0)] (1)
[0089] Among them, I f = Fractional emission intensity, I t = Fluorescence intensity at time t, I1 = Fluorescence intensity after adding Triton X-100, I0 = Initial fluorescence intensity.
[0090] The EC50 value and Hill coefficient n were obtained by fitting the curve of ion channel concentration versus ion transport activity R using Hill(S2).
[0091] R = 1 / (1+(EC) 50 / [aisle])n (2)
[0092] like Figure 1-2 As shown, the HPTS experimental results indicate that all Pn-TPP molecules possess significant ion transport capabilities. Figure 1 The ion transport activity of Pn-TPPs was affected by the length of the PEG linker. The results showed that the ion transport activity of Pn-TPPs was consistently enhanced as the PEG was extended from triethylene glycol to heptaethylene glycol. Therefore, P7-TPP exhibited the highest activity, showing 82% ion transport activity at a concentration of 10 μM after background correction. The transport activity of P7-TPP at different concentrations was determined... Figure 1 ), the corresponding EC 50 The value is 4.7 μM.
[0093] HPTS vesicle fluorescence experiments can also be performed by changing the type of alkali metal ions (M...) in the external buffer solution. + =Li + Na + ,K + ,Rb + Cs + To detect the channel's selectivity for alkali metal ions.
[0094] This invention investigates the cation selectivity of P7-TPP. For example... Figure 3 As shown, replacing the extracellular buffer from LiCl to CsCl resulted in virtually no change in ion transport activity, indicating that alkali metal ions did not participate in the ion transport process. Considering the inherent structural characteristics of P7-TPP, which lack strong metal ion-binding groups, this invention can confidently exclude Na+. + / OH - Cotransport and Na + / H + Antitransport is the primary ion transport mechanism. Therefore, the main mechanism of P7-TPP-promoted ion transport is either Cl... - / H + Co-transportation, or Cl - / OH - Reverse transfer.
[0095] Further comparison of Cl in HPTS assays was performed using a highly active proton transporter—the carbonyl cyanide of p-fluoromethoxyphenylhydrazine (FCCP). - and H + Ion transport rates between (e.g.) Figure 4 (As shown). And through highly active K + Selective transporter—valinemycin (VA) compared to Cl - and OH- Ion transport rate (e.g.) Figure 5 (As shown).
[0096] Compared to the 8% transmission efficiency observed with FCCP alone and the 53% efficiency observed with P7-TPP alone, the combination of P7-TPP and FCCP resulted in a significant improvement in transmission efficiency. The existence of a synergistic effect between P7-TPP and FCCP indicates that Cl - The transmission rate is higher than H + Faster. Furthermore, the combination of valvaline (10.0 pM) and P7-TPP (4.7 μM) showed no synergistic effect, indicating that Cl... - The transmission of OH takes precedence over OH. - .
[0097] Ion transport studies based on SPQ vesicle fluorescence experiments:
[0098] 1.0 mL of a chloroform solution of egg-yolk phosphatidylcholine (EYPC, 25 mg / mL) was placed in a round-bottom flask. The solvent was removed under reduced pressure at room temperature, and the flask was dried overnight under high vacuum. 1.0 mL of a 200 mM NaNO3 solution containing 0.5 mM of the chloride-sensitive dye 6-methoxy-N-(3-sulfopropyl)quinoline (SPQ) was shaken at room temperature for hydration. After 1 hour, the round-bottom flask was frozen in liquid nitrogen for 1 minute, then heated in a water bath at room temperature for 2 minutes. This freeze-thaw cycle was repeated 10 times. The suspension was then passed through a 100 nm pore size polycarbonate membrane and extruded 21 times to obtain a uniformly sized vesicle (LUV) suspension. Finally, the uncoated fluorescent dye in the LUV suspension was dialyzed off using a dialysis membrane to produce a 6.5 mM lipid LUV.
[0099] Add 30 μL of LUV suspension coated with SPQ to 1.95 mL of NaCl solution (200 mM) to generate extravesicular Cl. - Gradient. After adding channels of different concentrations with stirring, the emission of SPQ was monitored using a fluorescence spectrophotometer (Hitachi, model F-7100, Japan) at an excitation wavelength of 360 nm and an emission wavelength of 430 nm for a duration of 300 seconds. The fluorescence intensity was normalized after the addition of triton to obtain the final transport trajectory.
[0100] I f =(I t -I1) / (I0-I1) (3)
[0101] Where If = fractional emission intensity, It = fluorescence intensity at time t, I1 = fluorescence intensity after adding Triton X-100, and I0 = initial fluorescence intensity.
[0102] like Figure 6 As shown, adding P7-TPP from 0.02 to 1.25 μM (i.e., 0.02 to 1.25 mol%) to the LUV of the chloride ion-sensitive dye SPQ resulted in rapid, concentration-dependent quenching of SPQ fluorescence. This finding confirms that P7-TPP promotes the fluorescence quenching of chloride ions. - It exhibits significant activity in ion transmembrane transport. Figure 7 Other Pn-TPPs can also mediate chloride ion transport across the membrane, and the trend of chloride ion transport activity is consistent with that in the HPTS assay.
[0103] Research on the transport mechanism based on carboxyfluorescein permeation experiment:
[0104] 1.0 mL of egg-yolk phosphatidylcholine (EYPC, 25 mg / mL) chloroform solution was placed in a round-bottom flask, and the solvent was removed under reduced pressure at room temperature. The flask was then dried overnight under high vacuum. Hydration was performed by shaking at room temperature with a HEPES buffer solution containing 5(6)-fluorescein (CF, 50 mM) (1.0 mL, 10 mM HEPES, 100 mM NaCl, pH = 7.5). After 1 hour, the round-bottom flask was frozen in liquid nitrogen for 1 minute and then heated in a water bath at room temperature for 2 minutes. This freeze-thaw cycle was repeated 10 times. The suspension was then passed through a polycarbonate membrane with a pore size of 100 nm for 21 extrusions to obtain a uniformly sized vesicle (LUV) suspension. Finally, the uncoated fluorescent dye in the LUV suspension was dialyzed off using a dialysis membrane to produce a lipid LUV with a concentration of 6.5 mM.
[0105] 30 μL of LUV suspension coated with CF dye was added to 1.95 mL of HEPES buffer (1.95 mL, 10 mM HEPES, 100 mM NaCl, pH 7.5). After adding different concentrations of the CF dye to the channel with stirring, the emission of the CF dye was monitored using a fluorescence spectrophotometer (Hitachi, model F-7100, Japan) at an excitation wavelength of 492 nm and an emission wavelength of 517 nm for 300 seconds. The fluorescence intensity was normalized after the addition of triton to obtain the final transmission trajectory.
[0106] F = [(F t -F0) / (F1-F0)] (4)
[0107] Where F = fractional emission intensity, Ft = Fluorescence intensity at time t, F1 = Fluorescence intensity after adding Triton X-100, F0 = Initial fluorescence intensity.
[0108] Experiments on large monolayer vesicles (LUVs) encapsulating CF dye showed that introducing P7-TPP into LUVs at a concentration of 2.0 μM did almost no enhancement of CF fluorescence (e.g., Figure 8 As shown in the figure, this indicates that the integrity of the LUV membrane was maintained upon exposure to 2.0 μM P7-TPP. Given that P7-TPP mediated chloride ion transport with a high efficiency of 1.25 μM in the SPQ assay, this implies that Cl... - It is possible that the CF dye is transported across the membrane via chloride ion channels. Surprisingly, a significant enhancement of CF fluorescence was observed with further increases in P7-TPP concentration, indicating the possible formation of macropores with nanoscale cavities, whose ion transport properties may differ from those formed at lower concentrations. Therefore, this invention determined the ability of Pn-TPPs to self-assemble into nanopores at higher concentrations. As shown in Table 1, all five Pn-TPPs exhibited the ability to self-assemble into nanopores to transport CF dye at concentrations exceeding 5.0 μM. Moreover, extending the PEG length in Pn-TPPs from triethylene glycol to pentaethylene glycol significantly improved nanopore formation, as shown by EC 50 The value decreased significantly. However, further extension to heptaethylene glycol appears to affect nanopore formation. Among the five Pn-TPPs, P5-TPP exhibited the highest activity in nanopore formation, with an EC value of [value missing]. 50 The value is 16.1 μM, which may be attributed to the length of the PEG chain in P5-TPP, which allows the formed nanopores to better adapt to the hydrophobic regions of the membrane.
[0109] Table 1. EC values determined by CF dye penetration test 50 Value (μM)
[0110]
[0111] Planar lipid bilayer experiments demonstrate that compounds are transported via an adaptive channel mechanism:
[0112] Take 20 μL of DiPhyPC (1,2-diphytanoyl-sn-glycero-3-phosphocholine, 10 mg / mL) phospholipid chloroform solution into a sample vial, dry it under nitrogen, and then dissolve it in 8 μL of n-decane solvent. Then... A 0.5 μL solution of phospholipid in n-decane was applied to the small well of the cup and dried with nitrogen gas. In the patch-clamp experiment, in the chamber (cis side) and Add 1 mL of 1 M KCl solution to each of the beakers (trans side), insert the Ag-AgCl electrode into the KCl solution, and ground the cis chamber. In the pretreated... A DiPhyPC n-decane solution was coated onto the small well of a cup using a dip-coating method to form a film. Then, a DMSO solution containing channel molecules was added to the cis terminus. After a stable channel was formed, the single-molecule channel current was detected using a Warner BC-535D double-layer patch-clamp amplifier under an applied voltage. Data was collected using PatchMaster (HEKA) and analyzed using FitMaster (HEKA) (filter frequency 100Hz). The current signal was recorded from -160mV to +160mV, and the channel conductivity was obtained from the current-voltage relationship graph. Finally, the channel aperture size was calculated using the Hille equation.
[0113] The channel aperture size was obtained from the ionic conductivity calculated using the Hille equation (S5):
[0114] 1 / g=(l+πd / 4)×(4ρ / (πd2)) (5)
[0115] Where g = corrected ionic conductivity (obtained by multiplying the measured conductivity by Sansom's correction factor), The resistivity of the KCl solution with a density of ρ = 1 M is 0.0921 Ω·m.
[0116] This invention fabricated a bilayer film using a P5-TPP to DiPhyPC molar ratio of 1:5000. Single-channel current tracking was recorded by applying different voltages from -160mV to 160mV. Figure 9 As shown in Figure a, the "square" single-channel current tracer observed under different applied voltages clearly confirms that P5-TPP promotes Cl through a channel mechanism rather than a carrier mechanism. - Transmembrane transport of ions. This invention determines the transport of Cl- ions by linearly fitting current-voltage (IV) curves. - The conductivity of the ion channel is 8.5 ± 0.1 pS. Using the Hille equation, the pore size of the channel was estimated to be 0.19 nm in diameter.
[0117] In the next step, the present invention prepared a bilayer membrane composed of P5-TPP and DiPhyPC in a molar ratio of 1:1000. For example... Figure 9As shown in Figure c, a fairly large "square" single-channel current tracer was observed, providing compelling evidence for the formation of barrel-hoop channels with larger cavities. By linearly fitting the IV curve, the conductivity of the formed channel was calculated to be 250.0 ± 2.5 pS, and the estimated pore size of the formed channel was 1.14 nm in diameter, confirming the formation of nanopores. These findings confirm that P5-TPP forms channels of different sizes depending on its concentration in lipids.
[0118] Example 4
[0119] Detection of anticancer activity and mechanism of the compound
[0120] Studies on anticancer activity and selectivity:
[0121] Human hepatocellular carcinoma cells (HepG2 cell line) and human embryonic liver epithelial cells (HHL-5 cell line) were selected as the test cells for this study. 1 × 10⁶ cells were seeded in each well of a 96-well plate. 4 Cells were cultured overnight in DMEM medium containing 5% penicillin, 10% fetal bovine serum, and 2 mL of β-glutamate at 37°C with 5% CO2. Then, a series of solutions of different concentrations were prepared by dissolving the sample in DMSO and added to the medium. The cells were then cultured again at 37°C in a normoxic environment with 5% CO2 for 24 hours. Finally, 150 μL of DMSO solution was added to the medium, and the plates were shaken to completely dissolve the purple formazan crystals. The fluorescence of the solution was detected using a microplate reader to determine cell viability, and the anticancer activity and safety of the channel were calculated. The IC50 of the anticancer activity of Pn-TPPs against HepG2 and HHL-5 cells was determined. 50 The values and selectivity indices are summarized in Table 2.
[0122] Table 2. Anticancer activity of the IC50 channel against human hepatocellular carcinoma cells and human embryonic hepatic epithelial cells 50 Value and selectivity index
[0123]
[0124] All five Pn-TPPs exhibited good anticancer activity. The observed anticancer activity was consistent with the trend observed in the CF dye permeation experiment, thus confirming a strong correlation between nanopore formation and the final anticancer effect. The most active molecule, P5-TPP, showed doxorubicin-like anti-hepatocellular carcinoma activity (IC50). 50 =3.8 μM). Even more excitingly, P5-TPP exhibited excellent specificity against liver cancer cells, with a selectivity index of 4.4 against normal liver cells. Compared to doxorubicin, P5-TPP showed 16.8 times higher specificity against cancer cells.
[0125] Channels are specifically located in mitochondria:
[0126] HepG2 cells were used at a rate of 1×10 6 Cells were seeded at a suitable concentration in glass-bottomed culture dishes. After culturing for 12 hours in a 37°C, 5% CO2 incubator, cells were treated with 5 μM P5-TPP-py for 12 hours. After removing the cell culture medium, cells were washed once with 1X PBS and then incubated with 1 mL Mito-Tracker Red CMXRos working solution (200 nM) at 37°C for 30 minutes. Subsequently, the Mito-Tracker Red CMXRos working solution was removed, and fresh DMEM medium was added. Fluorescence images were acquired using a laser confocal microscope (LSM5 EXCITER, Zeiss).
[0127] To demonstrate the mitochondrial targeting ability of P5-TPP, this invention combines it with a pyrene group to form a fluorescent compound labeled P5-TPP-py. Subsequently, HepG2 cells were co-incubated with P5-TPP-py and the commercially available mitochondrial fluorescent dye MitoTracker Red. Figure 10 As shown, fluorescence imaging results revealed a significant overlap between the blue fluorescence signal emitted by P5-TPP-py and MitoTracker Red staining, presenting a pinkish cell population. Fluorescence intensity spectral analysis elucidated the strong concordance between the linear profiles of P5-TPP-py and MitoTracker Red. Quantitative fluorescence intensity analysis of the scatter plot showed a high degree of co-localization of the blue and red fluorescence signals, confirmed by a Pearson correlation coefficient of 0.76. These results confirm the specific localization of P5-TPP-py in mitochondria.
[0128] Flow cytometry:
[0129] In a 6-well plate, inoculate ~10 seeds per well. 5 HepG2 cells were cultured for 12 hours at 37°C and 5% CO2, followed by 24 hours of culture with different concentrations of molecular machinery solutions. Floating cells were collected and washed twice with PBS. Cells in 6-well plates were washed with PBS, digested with EDTA-free trypsin, collected, centrifuged, washed twice with PBS, and then combined with cells collected from the culture medium. After centrifugation, binding buffer was added to adjust the cell concentration to 102. 6 Cells were incubated at 100 μL per cell, with 5 μL of FITC-Annexin-V and 10 μL of PI solution added. The cells were then incubated at room temperature in the dark for 15 minutes. Cells were then analyzed using flow cytometry, and the data were analyzed using Flow J software to determine whether the pathway could promote apoptosis, and whether it was early or late apoptosis.
[0130] like Figure 11 As shown, as the P5-TPP concentration increased from 0 to 20 μM, the percentage of apoptotic cancer cells increased from 2.3% to 20.1%, confirming the ability of P5-TPP to induce apoptosis in cancer cells.
[0131] Study on changes in mitochondrial membrane potential in HepG2 cells
[0132] HepG2 cells were fed at a rate of 1×10 5 Cells were seeded at a density suitable for their size in glass-bottomed culture dishes. After culturing for 12 hours at 37°C and 5% CO2, different concentrations of P5-TPP solution were added, and the cells were cultured for another 24 hours. Subsequently, the culture medium was removed, the cells were washed once with 1×PBS, and 1.0 mL of cell culture medium was added, followed by 1.0 mL of JC-1 (1×) staining working solution, and mixed well. After culturing for 20 minutes at 37°C and 5% CO2, the supernatant was aspirated. Finally, the cells were washed twice with JC-1 staining buffer (1×), and 1.0 mL of cell culture medium was added. Fluorescence images were obtained using a laser confocal microscope.
[0133] In normal mitochondrial membranes, JC-1 fluorescent dye exists as J-aggregates, primarily emitting red fluorescence. However, when the mitochondrial membrane depolarizes, these aggregates disaggregate, resulting in green fluorescence. Compared to the control group, the addition of P5-TPP significantly enhanced green fluorescence and weakened red fluorescence, exhibiting a clear concentration-dependent effect. Figure 12 (As shown in Figure a). The degree of mitochondrial depolarization can be measured by the ratio of red to green fluorescence intensity. Quantitative analysis of the red / green fluorescence intensity ratio in cells showed that the addition of P5-TPP significantly enhanced the degree of mitochondrial membrane potential depolarization (as shown in Figure a). Figure 12 (As shown in b).
[0134] Intracellular ROS content measurement:
[0135] HepG2 cells were used at a rate of 6 × 10 5 Cells were evenly distributed in glass-bottomed culture dishes and cultured for 12 hours in an incubator containing 5% CO2 at 37°C. After incubation with different concentrations (0, 5, 10 μM) of P5-TPP, cells were detached from the culture dishes using 0.25% trypsin (1.0 mL) and then centrifuged at 112 × g for 5 minutes. The resulting cell pellet was washed twice with PBS (2.0 mL) and stained with DCFH-DA (10 mM) for 20 minutes. The cells were then washed three times with DMEM and resuspended in 1.0 mL of DMEM. The relative levels of reactive oxidative substances (ROS) in the cells were assessed by flow cytometry. The acquired data were analyzed using FlowJo 10.6.2.
[0136] Since mitochondrial membrane depolarization easily leads to an increase in intracellular reactive oxygen species (ROS) levels, this invention further utilizes the DCFH ROS probe to detect changes in intracellular ROS levels. The results show that when the P5-TPP concentration is 20 μM, the average fluorescence intensity of cells increases by 20%. Figure 13 This indicates that the introduction of P5-TPP significantly increases the level of intracellular ROS.
[0137] Studies on the release of cytochrome c:
[0138] HepG2 cells were used at a rate of 1×10 6 Cells were transplanted at a density of 10 cells / well onto glass coverslips. Subsequently, cells were fixed with 4% formalin and incubated with 0.5% Triton-X at 4°C for 10 minutes. After blocking with 10% (v / v) FBS, cells were stained overnight with cytochrome c antibody at 4°C. Following staining, cells were washed with 1×PBS and then incubated with fluorescent secondary antibody. Finally, cell boundaries were stained with phalloidin, and the cells were transferred to slides for observation of cytochrome c localization and fluorescence intensity using a laser confocal microscope.
[0139] like Figure 14 As shown, elevated ROS levels cause the opening of the mitochondrial permeability transition pore, leading to the release of cytochrome c. Compared to the control group, HepG2 cells treated with P5-TPP at a concentration of 20 μM showed a significant enhancement of green fluorescence, indicating the release of cytochrome c from the mitochondria.
[0140] Western blot analysis of apoptosis-related protein expression:
[0141] In a 6-well plate, inoculate ~10 seeds per well. 5Cells were cultured at 37°C and 5% CO2 for 12 hours, followed by 24 hours of culture with different concentrations of P5-TPP solution. After washing twice with pre-cooled PBS, 200 μL of RIPA high-efficiency lysis solution (containing 2% protease, 2% phosphatase inhibitor, and 2% EDTA) was added, and lysis was performed on ice for 10 minutes. Protein concentration was determined by BCA method, and after adjusting the sample protein concentration, loading buffer was added, followed by boiling for denaturation. Separation was performed using 10% SDS-PAGE. The separated protein samples were transferred to a PVDF (0.22 μm) membrane at 200 mA. After 55 minutes of transfer, the transferred PVDF membrane was placed in 5% skim milk powder (prepared with 1×TBSB buffer) and blocked on a horizontal shaker for 2 hours at room temperature. Different bands were incubated overnight at 4°C with their respective primary antibodies. After incubation, the bands were washed three times with 1×TBST and then incubated with goat antibody IgG H+L secondary antibody for 2 hours. Wash three times with 1×TBST buffer, develop color with ECL reagent, observe and photograph using an exposure meter. Measure grayscale values using ImageJ software, repeat three times, and statistically analyze the results.
[0142] like Figure 15 As shown, P5-TPP treatment of HepG2 cells led to the downregulation of anti-apoptotic proteins MCL1 and BCL2, indicating the ability of P5-TPP to promote apoptosis by regulating the mitochondrial pathway. Simultaneously, this invention found downregulation of caspase 9 and PARP, accompanied by a significant upregulation of cleaved PARP, indicating that P5-TPP activates the caspase 9 signaling pathway to induce apoptosis.
[0143] Although the above embodiments have been described, those skilled in the art, once they understand the basic inventive concept, can make other changes and modifications to these embodiments. Therefore, the above descriptions are merely embodiments of the present invention and do not limit the scope of patent protection of the present invention. Any equivalent structural or procedural transformations made using the content of the present invention's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the scope of patent protection of the present invention.
Claims
1. A compound Pn-TPP, characterized in that, The general structural formula of the compound Pn-TPP is as follows: ; Where n takes values from 3 to 7.
2. The method for preparing compound Pn-TPP according to claim 1, characterized in that, The synthetic route for the compound Pn-TPP is as follows: 。 3. The compound Pn-TPP according to claim 1, characterized in that, The compound Pn-TPP is compound P5-TPP, which self-assembles into chloride ion channels at low concentrations and into nanopores capable of transporting small molecules across membranes at high concentrations; the low concentration is ≤1.25 μM and the high concentration is ≥4 μM.
4. An application of the compound Pn-TPP according to any one of claims 1-3, characterized in that, The use of the compound Pn-TPP in the preparation of an antitumor drug, wherein the antitumor drug is an anti-liver cancer drug.
5. A pharmaceutical composition comprising the compound Pn-TPP as described in any one of claims 1-3 and a pharmaceutically acceptable carrier and / or excipient.
